Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® Hemoadsorption
A 67-year-old woman with a history of end-stage renal disease on hemodialysis received a therapeutic dose (150 mg daily) of flecainide for three weeks. She was admitted to the Emergency Department for malaise and dizziness, and the electrocardiogram revealed ventricular tachycardia treated by amioda...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2019/1905871 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555902358519808 |
|---|---|
| author | Nicolas De Schryver Philippe Hantson Vincent Haufroid Mélanie Dechamps |
| author_facet | Nicolas De Schryver Philippe Hantson Vincent Haufroid Mélanie Dechamps |
| author_sort | Nicolas De Schryver |
| collection | DOAJ |
| description | A 67-year-old woman with a history of end-stage renal disease on hemodialysis received a therapeutic dose (150 mg daily) of flecainide for three weeks. She was admitted to the Emergency Department for malaise and dizziness, and the electrocardiogram revealed ventricular tachycardia treated by amiodarone. Hemodynamic condition remained stable, and the toxicity of flecainide was initially not suspected until she developed within 8 hours a cardiogenic shock requiring vasopressors. The patient then received sodium bicarbonate (300 mmol) and dobutamine but experienced cardiac arrest two hours later. The administration of intravenous fat emulsion (IFE) was associated with return of spontaneous circulation, but there was a relapse of cardiovascular shock at the end of IFE infusion. The patient was placed on extracorporeal cardiac life support (ECLS), continuous hemofiltration, and hemoadsorption using the CytoSorb® cartridge. Serial determinations of serum flecainide concentration were obtained during the course of hemoadsorption, with a terminal half-life of 3.7 h during the first four hours and a global plasma clearance of 40.3 ml/min over the first 22 hours. The weaning of ECLS was possible on day 7. Intravenous fat emulsion infusion was followed by a significant increase in serum flecainide concentration. In addition, while conventional techniques of extrarenal epuration usually appear as poorly effective for flecainide removal, a mean plasma clearance of 40.3 ml/min was observed using the hemoadsorption technique based on CytoSorb® cartridge. However, the impact on the clinical course was probably extremely modest in comparison with ECLS. |
| format | Article |
| id | doaj-art-0ae3439ca66b407d80e92a480e9e53cb |
| institution | Kabale University |
| issn | 2090-6404 2090-6412 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Cardiology |
| spelling | doaj-art-0ae3439ca66b407d80e92a480e9e53cb2025-02-03T05:46:47ZengWileyCase Reports in Cardiology2090-64042090-64122019-01-01201910.1155/2019/19058711905871Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® HemoadsorptionNicolas De Schryver0Philippe Hantson1Vincent Haufroid2Mélanie Dechamps3Department of Intensive Care, Clinique St-Pierre, 1340 Ottignies, BelgiumDepartment of Intensive Care, Cliniques St-Luc, Université catholique de Louvain, 1200 Brussels, BelgiumLouvain Centre of Toxicology and Applied Pharmacology, Université catholique de Louvain, 1200 Brussels, BelgiumCardiovascular Intensive Care, Cliniques St-Luc, Université catholique de Louvain, 1200 Brussels, BelgiumA 67-year-old woman with a history of end-stage renal disease on hemodialysis received a therapeutic dose (150 mg daily) of flecainide for three weeks. She was admitted to the Emergency Department for malaise and dizziness, and the electrocardiogram revealed ventricular tachycardia treated by amiodarone. Hemodynamic condition remained stable, and the toxicity of flecainide was initially not suspected until she developed within 8 hours a cardiogenic shock requiring vasopressors. The patient then received sodium bicarbonate (300 mmol) and dobutamine but experienced cardiac arrest two hours later. The administration of intravenous fat emulsion (IFE) was associated with return of spontaneous circulation, but there was a relapse of cardiovascular shock at the end of IFE infusion. The patient was placed on extracorporeal cardiac life support (ECLS), continuous hemofiltration, and hemoadsorption using the CytoSorb® cartridge. Serial determinations of serum flecainide concentration were obtained during the course of hemoadsorption, with a terminal half-life of 3.7 h during the first four hours and a global plasma clearance of 40.3 ml/min over the first 22 hours. The weaning of ECLS was possible on day 7. Intravenous fat emulsion infusion was followed by a significant increase in serum flecainide concentration. In addition, while conventional techniques of extrarenal epuration usually appear as poorly effective for flecainide removal, a mean plasma clearance of 40.3 ml/min was observed using the hemoadsorption technique based on CytoSorb® cartridge. However, the impact on the clinical course was probably extremely modest in comparison with ECLS.http://dx.doi.org/10.1155/2019/1905871 |
| spellingShingle | Nicolas De Schryver Philippe Hantson Vincent Haufroid Mélanie Dechamps Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® Hemoadsorption Case Reports in Cardiology |
| title | Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® Hemoadsorption |
| title_full | Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® Hemoadsorption |
| title_fullStr | Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® Hemoadsorption |
| title_full_unstemmed | Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® Hemoadsorption |
| title_short | Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® Hemoadsorption |
| title_sort | cardiogenic shock in a hemodialyzed patient on flecainide treatment with intravenous fat emulsion extracorporeal cardiac life support and cytosorb r hemoadsorption |
| url | http://dx.doi.org/10.1155/2019/1905871 |
| work_keys_str_mv | AT nicolasdeschryver cardiogenicshockinahemodialyzedpatientonflecainidetreatmentwithintravenousfatemulsionextracorporealcardiaclifesupportandcytosorbhemoadsorption AT philippehantson cardiogenicshockinahemodialyzedpatientonflecainidetreatmentwithintravenousfatemulsionextracorporealcardiaclifesupportandcytosorbhemoadsorption AT vincenthaufroid cardiogenicshockinahemodialyzedpatientonflecainidetreatmentwithintravenousfatemulsionextracorporealcardiaclifesupportandcytosorbhemoadsorption AT melaniedechamps cardiogenicshockinahemodialyzedpatientonflecainidetreatmentwithintravenousfatemulsionextracorporealcardiaclifesupportandcytosorbhemoadsorption |